Company profile
Genenta Science S.p.A.
NASDAQ:GNTABiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06716853 | phase1_2 | terminated | 2024-10-22 | 2026-01-23 | Genenta Science | A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma |
| NCT03875495 | phase1_2 | terminated | 2019-03-06 | 2021-04-02 | Genenta Science | A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) |
| NCT03866109 | phase1_2 | terminated | 2019-03-05 | 2026-05-27 | Genenta Science | A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT |
FDA applications (0)
No records yet.